Krishna Surapaneni1, Benjamin C Kennedy2, Ted K Yanagihara3, Robert DeLaPaz4, Jeffrey N Bruce2. 1. Department of Radiology, Columbia University Medical Center, New York, New York, USA. Electronic address: krishna123@gmail.com. 2. Department of Neurological Surgery, Columbia University Medical Center, New York, New York, USA. 3. Department of Neuroscience, Columbia University Medical Center, New York, New York, USA. 4. Department of Radiology, Columbia University Medical Center, New York, New York, USA.
Abstract
OBJECTIVE: To assess whether early changes in enhancing tumor volume (eTV) and relative cerebral blood volume (rCBV) 1 month after convection-enhanced delivery of topotecan in patients with recurrent malignant glioma correlated with 6-month disease progression status. METHODS: Sixteen patients were enrolled in a Phase Ib trial of convection-enhanced delivery of topotecan for recurrent malignant glioma. Each patient was evaluated with serial follow-up magnetic resonance imaging at baseline and at 4- to 8-week intervals. Changes at 1 month compared with baseline in eTV and rCBV were evaluated as potential predictors of 6-month progression status, classified as either progressive disease or nonprogressive disease. Relationships between percent changes in eTV and rCBV at 1 month with the probability of progressive disease at 6 months were estimated by the use of logistic regression analysis. Receiver operating characteristic curves for varying percent change thresholds in eTV and rCBV were evaluated by the use of 6-month progressive disease as the reference. RESULTS: There was a significant difference in the percent change in rCBV at 1 month in patients with progressive disease compared with those with nonprogressive disease at 6 months (+12% vs. -29%, P = 0.02). Logistic regression analysis demonstrated on average that a 10% increase in rCBV at 1 month after convection-enhanced delivery of topotecan was associated with 1.7 times the odds of developing progressive disease at 6 months (95% confidence interval [CI] 1.0-2.9 P = 0.05). Receiver operating characteristic analysis for determining progressive disease at 6 months showed a greater area under the curve with rCBV (0.867; 95% CI 0.66-1.00) than with change in enhancing tumor volume (0.767; 95% CI 0.51-1.00). CONCLUSION: In this selected population of patients with recurrent malignant glioma treated with convection-enhanced delivery of topotecan, early changes in rCBV at 4 weeks after therapy may help predict progression status at 6 months.
OBJECTIVE: To assess whether early changes in enhancing tumor volume (eTV) and relative cerebral blood volume (rCBV) 1 month after convection-enhanced delivery of topotecan in patients with recurrent malignant glioma correlated with 6-month disease progression status. METHODS: Sixteen patients were enrolled in a Phase Ib trial of convection-enhanced delivery of topotecan for recurrent malignant glioma. Each patient was evaluated with serial follow-up magnetic resonance imaging at baseline and at 4- to 8-week intervals. Changes at 1 month compared with baseline in eTV and rCBV were evaluated as potential predictors of 6-month progression status, classified as either progressive disease or nonprogressive disease. Relationships between percent changes in eTV and rCBV at 1 month with the probability of progressive disease at 6 months were estimated by the use of logistic regression analysis. Receiver operating characteristic curves for varying percent change thresholds in eTV and rCBV were evaluated by the use of 6-month progressive disease as the reference. RESULTS: There was a significant difference in the percent change in rCBV at 1 month in patients with progressive disease compared with those with nonprogressive disease at 6 months (+12% vs. -29%, P = 0.02). Logistic regression analysis demonstrated on average that a 10% increase in rCBV at 1 month after convection-enhanced delivery of topotecan was associated with 1.7 times the odds of developing progressive disease at 6 months (95% confidence interval [CI] 1.0-2.9 P = 0.05). Receiver operating characteristic analysis for determining progressive disease at 6 months showed a greater area under the curve with rCBV (0.867; 95% CI 0.66-1.00) than with change in enhancing tumor volume (0.767; 95% CI 0.51-1.00). CONCLUSION: In this selected population of patients with recurrent malignant glioma treated with convection-enhanced delivery of topotecan, early changes in rCBV at 4 weeks after therapy may help predict progression status at 6 months.
Authors: Soonmee Cha; Edmond A Knopp; Glyn Johnson; Stephan G Wetzel; Andrew W Litt; David Zagzag Journal: Radiology Date: 2002-04 Impact factor: 11.105
Authors: K M Donahue; H G Krouwer; S D Rand; A P Pathak; C S Marszalkowski; S C Censky; R W Prost Journal: Magn Reson Med Date: 2000-06 Impact factor: 4.668
Authors: Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez Journal: AJNR Am J Neuroradiol Date: 2004-02 Impact factor: 3.825
Authors: T Sugahara; Y Korogi; M Kochi; I Ikushima; T Hirai; T Okuda; Y Shigematsu; L Liang; Y Ge; Y Ushio; M Takahashi Journal: AJR Am J Roentgenol Date: 1998-12 Impact factor: 3.959
Authors: Seymur Gahramanov; Leslie L Muldoon; Csanad G Varallyay; Xin Li; Dale F Kraemer; Rongwei Fu; Bronwyn E Hamilton; William D Rooney; Edward A Neuwelt Journal: Radiology Date: 2012-11-30 Impact factor: 11.105
Authors: Ian F Parney; Sandeep Kunwar; Michael McDermott; Mitchel Berger; Michael Prados; Soonmee Cha; David Croteau; Raj K Puri; Susan M Chang Journal: J Neurosurg Date: 2005-02 Impact factor: 5.408
Authors: K M Schmainda; M A Prah; L S Hu; C C Quarles; N Semmineh; S D Rand; J M Connelly; B Anderies; Y Zhou; Y Liu; B Logan; A Stokes; G Baird; J L Boxerman Journal: AJNR Am J Neuroradiol Date: 2019-03-28 Impact factor: 3.825
Authors: Roger Gilabert-Oriol; Lina Chernov; Malathi Anantha; Wieslawa H Dragowska; Marcel B Bally Journal: Drug Deliv Transl Res Date: 2017-08 Impact factor: 4.617